Compare TGLS & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGLS | AAPG |
|---|---|---|
| Founded | 1984 | 2009 |
| Country | United States | China |
| Employees | N/A | 767 |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2011 | N/A |
| Metric | TGLS | AAPG |
|---|---|---|
| Price | $39.45 | $19.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $63.33 | $48.40 |
| AVG Volume (30 Days) | ★ 309.6K | 4.3K |
| Earning Date | 05-07-2026 | 05-20-2026 |
| Dividend Yield | ★ 1.41% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.71 | N/A |
| Revenue | ★ $370,984,000.00 | N/A |
| Revenue This Year | $13.56 | $290.34 |
| Revenue Next Year | $9.04 | N/A |
| P/E Ratio | $54.41 | ★ N/A |
| Revenue Growth | ★ 17.98 | N/A |
| 52 Week Low | $37.52 | $19.11 |
| 52 Week High | $90.34 | $48.45 |
| Indicator | TGLS | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 42.36 | 29.60 |
| Support Level | N/A | N/A |
| Resistance Level | $46.89 | $25.23 |
| Average True Range (ATR) | 2.05 | 0.57 |
| MACD | -0.28 | -0.28 |
| Stochastic Oscillator | 20.29 | 14.99 |
Tecnoglass Inc is a manufacturer of hi-spec architectural glass and windows for residential and commercial construction industries, operating through its direct and indirect subsidiaries. Its product offerings include tempered glass, laminated glass, thermo-acoustic glass, sliding windows, projecting windows, guillotine windows, sliding doors, loating facades, automatic doors, bathroom dividers, and commercial display windows, among others. The company has one operating segment, Architectural Glass and Windows, which is also its reporting segment. Geographically, the company generates maximum revenue from its customers in the United States, followed by Colombia, Panama, and other regions.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.